Markets:

Overview

News

Currencies

International

Treasuries

CorMedix Inc. - Common Stock (NQ:CRMD)

9.680 -0.040 (-0.41%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CorMedix Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Get insights into the top gainers and losers of Thursday's after-hours session. ↗

June 26, 2025

After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

Via Chartmill

Applied Materials To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

June 24, 2025

Via Benzinga

CorMedix Lifts Q2 Outlook As Dialysis Partner Expands DefenCath Use; Needham Raises PT To $20 ↗

June 23, 2025

DefenCath, CorMedix’s lead product, was launched in hospitals in April 2024 and in outpatient settings in July 2024 following FDA approval.

Via Stocktwits

Earnings Scheduled For May 6, 2025 ↗

May 06, 2025

Via Benzinga

Earnings Preview For Cormedix ↗

May 05, 2025

Via Benzinga

CorMedix Spikes To Four-Year High On A Surprise Deal For Its Leading Drug ↗

June 23, 2025

CorMedix shares bounded to a four-year high Monday after the biotech company inked an expanded deal for its leading drug.

Via Investor's Business Daily

CorMedix Stock Hits New 52-Week High On Updated Guidance: The Details ↗

June 23, 2025

CorMedix Inc (NASDAQ:CRMD) shares are hitting new 52-week highs on Monday after the company raised its sales guidance for the second quarter.

Via Benzinga

Kroger Posts Better-Than-Expected Earnings, Joins Couchbase, CarMax And Other Big Stocks Moving Higher On Friday ↗

June 23, 2025

Via Benzinga

CorMedix Q1 Earnings Trump Estimates: Retail’s Overjoyed ↗

May 06, 2025

The company reported net revenue of $39.1 million for the first quarter from the sales of DefenCath, above an analyst estimate of $36, as per Finchat data.

Via Stocktwits

Topics Earnings Government

CorMedix Stock Rises After Preliminary Q1 Results Exceeds Expectations: Retail’s Elated ↗

April 08, 2025

The company expects quarterly adjusted earnings before interest, taxes, depreciation, and amortisation (EBITDA) to exceed $22.5 million once final numbers are reported, exceeding expectations of $14.78...

Via Stocktwits

Marvell Technology, Nvidia, Tesla, Apple And Other Big Stocks Moving Higher On Tuesday ↗

April 08, 2025

Via Benzinga

CORMEDIX ALERT: Bragar Eagel & Squire, P.C. is Investigating CorMedix Inc. on Behalf of CorMedix Stockholders and Encourages Investors to Contact the Firm

March 27, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

CorMedix (CRMD) Q4 2024 Earnings Call Transcript ↗

March 25, 2025

CRMD earnings call for the period ending December 31, 2024.

Via The Motley Fool

Topics Earnings

Which stocks are experiencing notable movement on Tuesday? ↗

March 25, 2025

Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

March 25, 2025

Via Benzinga

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

March 25, 2025

The market is buzzing with gapping stocks on Tuesday. Let's uncover which stocks are experiencing notable gaps during today's session.

Via Chartmill

CorMedix Stock Loses Almost A Third Of Its Market Cap After Downbeat H1 Revenue Outlook – But Retail Shrugs It Off ↗

March 25, 2025

The company reported earnings of $0.22 per share compared with a loss of $0.26 per share in the corresponding period of 2023, owing to the launch of its lead product, DefenCath.

Via Stocktwits

Nasdaq Gains 50 Points; US New Home Sales Rise In February ↗

March 25, 2025

Via Benzinga

Which stocks are moving before the opening bell on Tuesday? ↗

March 25, 2025

Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Via Chartmill

Earnings Scheduled For March 25, 2025 ↗

March 25, 2025

Via Benzinga

CorMedix Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗

March 24, 2025

Via Benzinga

Li Auto, Xponential Fitness And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

March 14, 2025

Via Benzinga

Healthcare Stocks Doing Well But SMID Biotech Looking A Little Frazzled ↗

March 10, 2025

Small caps took another step down this past week as geopolitical events dampened sentiment.

Via Talk Markets

Topics ETFs Stocks / Equities

3 Value Stocks That Are Backed By The World’s Largest Activist Hedge Fund ↗

February 25, 2025

Sometimes, hedge funds make risky decisions. But these stocks are at the lower end of the exposure risk spectrum.

Via Talk Markets

Topics Stocks / Equities

Top movers in Friday's after hours session ↗

February 21, 2025

As the regular session of the US market concludes on Friday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

Elliott Investment Management Buys Wolfspeed Stock, Bets Against Nvidia In Q4 ↗

February 19, 2025

Elliott Investment Management made several portfolio moves in the fourth quarter, closing multiple options positions and shaking up the activist firm's technology exposure.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

January 07, 2025

Via Benzinga

Two Big Weeks To Play A Rally In Biotech And Healthcare Stocks ↗

January 06, 2025

The healthcare sector is lagging over the past year and recent quarter with the XLV flat for 2024 and down over 4% for the recent quarter.

Via Talk Markets

Topics ETFs Stocks / Equities

Smaller Cap Biotechs Are In Season: How Are We Doing? ↗

November 07, 2024

SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range.

Via Talk Markets

CorMedix (CRMD) Q3 2024 Earnings Call Transcript ↗

October 30, 2024

CRMD earnings call for the period ending September 30, 2024.

Via The Motley Fool

Topics Earnings

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

CorMedix Inc. - Common Stock (NQ:CRMD)

All News about CorMedix Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today